Therefore, the beneficial effects of LCHFD on obesity and NAFLD seem to be explained by the reduction in insulin secretion, which would limit both weight gain due to the accumulation of lipids in adipose tissue and de novo lipogenesis activation, but they not involve an increase of fatty oxidation pathway. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.